Julia Simwaka1,2, Mapaseka Seheri3, Gina Mulundu2, Patrick Kaonga4,5, Jason M Mwenda6, Roma Chilengi7, Evans Mpabalwani8, Sody Munsaka2. 1. Department of Pathology and Microbiology, School of Medicine, University of Zambia, Lusaka, Zambia. 2. Department of Biomedical Sciences, School of Health Sciences, University of Zambia, Lusaka, Zambia. 3. World Health Organization Regional Office for Africa (WHO/AFRO), Brazzaville, Congo. 4. Department of Epidemiology and Biostatistics, School of Public Health, University of Zambia, Lusaka, Zambia. 5. Department of Internal Medicine, University Teaching Hospital, Tropical Gastroenterology and Nutrition Group, Lusaka, Zambia. 6. Department of Virology, Diarrhoea Pathogens Research Unit and WHO AFRO Rotavirus Regional Reference Laboratory, South African Medical Research Council, Sefako Makgatho Health Sciences University, Pretoria, South Africa. 7. Center for Infectious Disease Research in Zambia, Lusaka, Zambia. 8. Department of Paediatric and Child Health, School of Medicine, University of Zambia, Lusaka, Zambia.
Abstract
BACKGROUND: In Zambia, before rotavirus vaccine introduction, the virus accounted for about 10 million episodes of diarrhoea, 63 000 hospitalisations and 15 000 deaths in 2015, making diarrhoea the third leading cause of death after pneumonia and malaria. In Zambia, despite the introduction of the vaccine acute diarrhoea due to rotaviruses has continued to affect children aged five years and below. This study aimed to characterise the rotavirus genotypes which were responsible for diarrhoeal infections in vaccinated infants aged 2 to 12 months and to determine the relationship between rotavirus strains and the severity of diarrhoea in 2016. METHODS: Stool samples from infants aged 2 to 12 months who presented to the hospital with acute diarrhoea of three or more episodes in 24 hours were tested for group A rotavirus. All positive specimens that had enough sample were genotyped using reverse transcriptase Polymerase Chain Reaction (RT-PCR). A 20-point Vesikari clinical score between 1-5 was considered as mild, 6-10 as moderate and greater or equal to 11 as severe. RESULTS: A total of 424 stool specimens were tested of which 153 (36%, 95% CI 31.5% to 40.9%) were positive for VP6 rotavirus antigen. The age-specific rotavirus infections decreased significantly (p = 0.041) from 2-4 months, 32.0% (49/118) followed by a 38.8% (70/181) infection rate in the 5-8 months' category and subsequently dropped in the infants aged 9-12 months with a positivity rate of 27.2%. 38.5% of infants who received a single dose, 34.5% of those who received a complete dose and 45.2% (19/42) of the unvaccinated tested positive for rotavirus. The predominant rotavirus genotypes included G2P[6] 36%, G1P[8] 32%, mixed infections 19%, G2P[4] 6%, G1P[6] 4% and G9P[6] 3%. DISCUSSION AND CONCLUSION: Results suggest breakthrough infection of heterotypic strains (G2P[6] (36%), homotypic, G1P[8] (32%) and mixed infections (19%) raises concerns about the effects of the vaccination on the rotavirus diversity, considering the selective pressure that rotavirus vaccines could exert on viral populations. This data indicates that the rotavirus vaccine has generally reduced the severity of diarrhoea despite the detection of the virus strains.
BACKGROUND: In Zambia, before rotavirus vaccine introduction, the virus accounted for about 10 million episodes of diarrhoea, 63 000 hospitalisations and 15 000 deaths in 2015, making diarrhoea the third leading cause of death after pneumonia and malaria. In Zambia, despite the introduction of the vaccine acute diarrhoea due to rotaviruses has continued to affect children aged five years and below. This study aimed to characterise the rotavirus genotypes which were responsible for diarrhoeal infections in vaccinated infants aged 2 to 12 months and to determine the relationship between rotavirus strains and the severity of diarrhoea in 2016. METHODS: Stool samples from infants aged 2 to 12 months who presented to the hospital with acute diarrhoea of three or more episodes in 24 hours were tested for group A rotavirus. All positive specimens that had enough sample were genotyped using reverse transcriptase Polymerase Chain Reaction (RT-PCR). A 20-point Vesikari clinical score between 1-5 was considered as mild, 6-10 as moderate and greater or equal to 11 as severe. RESULTS: A total of 424 stool specimens were tested of which 153 (36%, 95% CI 31.5% to 40.9%) were positive for VP6 rotavirus antigen. The age-specific rotavirus infections decreased significantly (p = 0.041) from 2-4 months, 32.0% (49/118) followed by a 38.8% (70/181) infection rate in the 5-8 months' category and subsequently dropped in the infants aged 9-12 months with a positivity rate of 27.2%. 38.5% of infants who received a single dose, 34.5% of those who received a complete dose and 45.2% (19/42) of the unvaccinated tested positive for rotavirus. The predominant rotavirus genotypes included G2P[6] 36%, G1P[8] 32%, mixed infections 19%, G2P[4] 6%, G1P[6] 4% and G9P[6] 3%. DISCUSSION AND CONCLUSION: Results suggest breakthrough infection of heterotypic strains (G2P[6] (36%), homotypic, G1P[8] (32%) and mixed infections (19%) raises concerns about the effects of the vaccination on the rotavirus diversity, considering the selective pressure that rotavirus vaccines could exert on viral populations. This data indicates that the rotavirus vaccine has generally reduced the severity of diarrhoea despite the detection of the virus strains.
Authors: Laura K Beres; Jacqueline E Tate; Lungowe Njobvu; Bertha Chibwe; Cheryl Rudd; M Brad Guffey; Jeffrey S A Stringer; Umesh D Parashar; Roma Chilengi Journal: Clin Infect Dis Date: 2016-05-01 Impact factor: 9.079
Authors: Maria Paulke-Korinek; Herwig Kollaritsch; Stephan W Aberle; Ines Zwazl; Birgit Schmidle-Loss; Andreas Vécsei; Michael Kundi Journal: Vaccine Date: 2013-04-15 Impact factor: 3.641
Authors: Jason M Mwenda; Kinkela Mina Ntoto; Almaz Abebe; Christabel Enweronu-Laryea; Ismail Amina; Jackson Mchomvu; Annet Kisakye; Evans M Mpabalwani; Isoro Pazvakavambwa; George E Armah; L M Seheri; Nicholas M Kiulia; N Page; Marc-Alain Widdowson; A Duncan Steele Journal: J Infect Dis Date: 2010-09-01 Impact factor: 5.226
Authors: Nigel A Cunliffe; Desiree Witte; Bagrey M Ngwira; Stacy Todd; Nancy J Bostock; Ann M Turner; Philips Chimpeni; John C Victor; A Duncan Steele; Alain Bouckenooghe; Kathleen M Neuzil Journal: Vaccine Date: 2012-04-27 Impact factor: 3.641
Authors: T Vesikari; A Karvonen; R Prymula; V Schuster; J C Tejedor; R Cohen; F Meurice; H H Han; S Damaso; A Bouckenooghe Journal: Lancet Date: 2007-11-24 Impact factor: 79.321
Authors: J C Simwaka; Evans M Mpabalwani; Mapaseka Seheri; Ina Peenze; Mwaka Monze; Belem Matapo; Umesh D Parashar; Jacob Mufunda; Jeffrey M Mphahlele; Jacqueline E Tate; Jason M Mwenda Journal: Vaccine Date: 2018-06-12 Impact factor: 3.641
Authors: L M Seheri; N B Magagula; I Peenze; K Rakau; A Ndadza; J M Mwenda; G Weldegebriel; A D Steele; M J Mphahlele Journal: Vaccine Date: 2017-12-02 Impact factor: 3.641